PriceTargets.com logo

Cardiol Therapeutics - CRDL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 732.12%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 2 Strong Buy Ratings
$0.96 As of 12/4/2025 05:00 PM ET
▲ +0.0172 (1.82%)

This chart shows the closing price for CRDL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardiol Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRDL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRDL

Analyst Price Target is $8.00
▲ +732.12% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cardiol Therapeutics in the last 3 months. The average price target is $8.00, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a 732.12% upside from the last price of $0.96.

This chart shows the closing price for CRDL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Cardiol Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$9.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/17/2025Brookline Capital ManagementUpgradeStrong-Buy
6/2/2025HC WainwrightInitiated CoverageBuy$9.00
4/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
2/24/2025HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
1/28/2025RODMAN&RENSHAWUpgradeStrong-Buy
1/28/2025Rodman & RenshawInitiated CoverageBuy$7.00
12/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
11/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
10/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
6/26/2024Roth CapitalUpgradeStrong-Buy
6/26/2024Roth MkmInitiated CoverageBuy$10.00
6/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
6/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
5/23/2024Canaccord Genuity GroupBoost TargetBuy$6.00 ➝ $8.00
5/23/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$6.00 ➝ $8.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
4/22/2024HC WainwrightInitiated CoverageBuy$9.00
9/19/2023Leede Jones GabReiterated RatingSpeculative Buy
8/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$3.00
11/8/2022Raymond James FinancialLower TargetC$3.00 ➝ C$1.00
9/1/2022Raymond James FinancialLower TargetC$4.00 ➝ C$3.00
4/19/2022Canaccord Genuity GroupLower Target$8.00 ➝ $7.00
12/17/2021Cantor FitzgeraldInitiated CoverageOverweight$8.00
8/25/2021Raymond James FinancialBoost TargetOutperformC$4.50 ➝ C$5.00
8/24/2021Leede Jones GabReiterated RatingSpeculative Buy
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cardiol Therapeutics logo
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Read More

Today's Range

Now: $0.96
Low: $0.92
High: $0.99

50 Day Range

MA: $1.06
Low: $0.93
High: $1.22

52 Week Range

Now: $0.96
Low: $0.77
High: $1.59

Volume

443,797 shs

Average Volume

592,489 shs

Market Capitalization

$95.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiol Therapeutics?

The following equities research analysts have issued stock ratings on Cardiol Therapeutics in the last twelve months: Brookline Capital Management, HC Wainwright, Rodman & Renshaw, RODMAN&RENSHAW, and Weiss Ratings.
View the latest analyst ratings for CRDL.

What is the current price target for Cardiol Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cardiol Therapeutics in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 732.1%. HC Wainwright has the highest price target set, predicting CRDL will reach $9.00 in the next twelve months. Rodman & Renshaw has the lowest price target set, forecasting a price of $7.00 for Cardiol Therapeutics in the next year.
View the latest price targets for CRDL.

What is the current consensus analyst rating for Cardiol Therapeutics?

Cardiol Therapeutics currently has 1 sell rating, 2 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRDL will outperform the market and that investors should add to their positions of Cardiol Therapeutics.
View the latest ratings for CRDL.

What other companies compete with Cardiol Therapeutics?

Other companies that are similar to Cardiol Therapeutics include Benitec Biopharma, PureTech Health, Tectonic Therapeutic, Akebia Therapeutics and Entrada Therapeutics. Learn More about companies similar to Cardiol Therapeutics.

How do I contact Cardiol Therapeutics' investor relations team?

The company's listed phone number is (289) 910-0850 and its investor relations email address is [email protected]. The official website for Cardiol Therapeutics is www.cardiolrx.com. Learn More about contacing Cardiol Therapeutics investor relations.